Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 15, 2025 13:00 ET | Source: DelveInsight Business Research LLP

Gastrointestinal Stromal Tumor Market to Grow Rapidly During the Study Period (2020–2034) Owing to the Launch of Emerging Therapies | DelveInsight

New York, USA, April 15, 2025 (GLOBE NEWSWIRE) -- Gastrointestinal Stromal Tumor Market to Grow Rapidly During the Study Period (2020–2034) Owing to the Launch of Emerging Therapies | DelveInsight ...
October 24, 2022 11:23 ET | Source: ReportLinker

The Global Gastrointestinal Stromal Tumors Therapeutics Market is expected to grow by $1.08 bn during 2022-2026, accelerating at a CAGR of 5.97% during the forecast period

New York, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Gastrointestinal Stromal Tumors Therapeutics Market 2022-2026" -...
October 19, 2022 13:00 ET | Source: DelveInsight Business Research LLP

24+ Key Companies Actively Working in the Gastrointestinal Stromal Tumor Pipeline Segment | DelveInsight

New York, USA, Oct. 19, 2022 (GLOBE NEWSWIRE) -- 24+ Key Companies Actively Working in the Gastrointestinal Stromal Tumor Pipeline Segment | DelveInsight Gastrointestinal stromal tumors (GISTs) are...
June 23, 2022 02:58 ET | Source: Immunicum AB

Immunicum AB: Immunicum tillkännager Corporate Rebranding och namnbyte till Mendus AB

Varumärkestransformationen återspeglar framstegen inom nästa generations cancerimmunterapier, den kommande tillverkningsexpansionen och företagets långsiktiga ambitionerBolagets aktie fortsätter att...
June 23, 2022 02:58 ET | Source: Immunicum AB

Immunicum AB: Immunicum Announces Corporate Rebranding and Name Change to Mendus AB

Rebranding reflects advancing pipeline in next generation cancer immunotherapies, upcoming manufacturing expansion, and long-term corporate aspirationsThe Company’s stock to continue trading under...
June 09, 2022 02:00 ET | Source: Immunicum AB

Immunicum AB: Immunicum har erhållit FDA-beteckning för särläkemedel för ilixadencel som behandling av gastrointestinala stromacellstumörer (GIST)

Immunicum AB (“ Immunicum ” publ ; IMMU.ST), ett bioläkemedelsföretag fokuserat på tumörrecidiv och svårbehandlade etablerade tumörer , meddelade idag att man har beviljats en Orphan Drug Designation...
June 09, 2022 02:00 ET | Source: Immunicum AB

Immunicum AB: Immunicum Received FDA Orphan Drug Designation for Ilixadencel as Treatment of Gastrointestinal Stromal Tumors (GIST)

Immunicum AB (“Immunicum” publ; IMMU.ST), a biopharmaceutical company focused on tumor recurrence and hard-to-treat established tumors, announced today that it has been granted an Orphan Drug...
June 01, 2022 02:00 ET | Source: Immunicum AB

Immunicum AB: Immunicum deltar i kommande konferenser

Immunicum AB (“Immunicum” publ; IMMU.ST), ett bioläkemedelsföretag fokuserat på behandlingar mot tumörrecidiv och svårbehandlade etablerade tumörer, tillkännagav idag sitt deltagande i följande...
June 01, 2022 02:00 ET | Source: Immunicum AB

Immunicum AB: Immunicum to Participate in Upcoming Conferences

Immunicum AB (publ; IMMU.ST), a biopharmaceutical company focused on therapies addressing tumor recurrence and hard-to-treat established tumors, today announced its participation in the following...
May 16, 2022 02:00 ET | Source: Immunicum AB

Immunicum AB: Immunicum tillkännager positiva interimsresultat från ADVANCE II-studie i AML-underhållsbehandling

Analys av primärstudiens effektmått slutfördes med 7 patienter som visade ett mätbar restsjukdom (MRD)-svar, varav 5 patienter konverterade från MRD+ till MRD- och 2 patienter som visade en avsevärd,...